<DOC>
	<DOCNO>NCT00365131</DOCNO>
	<brief_summary>This multicenter , open-label , prospective study efficacy Cerezyme treat patient skeletal manifestation secondary Type I Gaucher disease . The study objective evaluate quantify skeletal response compare baseline Type I gaucher disease patient receive Cerezyme therapy 48 month . Additional objectives assess usefulness various skeletal parameter , bone pain , bone crisis , bone mineral density , serum urine bone marker , indicative treatment response may useful dose management .</brief_summary>
	<brief_title>A Multicenter Study Efficacy Cerezyme Testing Skeletal Disease Patients With Type I Gaucher Disease .</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<criteria>Signed informed consent . Confirmed diagnosis Type I Gaucher disease , prior enzyme replacement therapy , gene therapy bone marrow transplantation , ambulatory . Age 1065 ( patient 6670 year age consider casebycase basis follow careful medical review ) . Dual energy Xray absorptiometry ( DEXA ) femoral nech Tscore ≤ 1.0 . One follow sign document Xray , compute tomography ( CT ) , magnetic resonance imaging ( MRI ) , symptoms bone disease document patient 's medical history baseline examination : ) . history least one bone crises ; b ) . Erlenmeyer flask deformity femur child ( 1017 year old ) ; c ) . osteoarticular necrosis ; ) . medullary infarction ; e ) . lytic lesion ; f ) . pathological fracture fracture relate Gaucher disease ; g ) . marrow infiltration degree Rosenthal 's Magnetic Resonance Score ≥ 3 ; h ) . bone density quantitative compute tomography ( QCT ) DEXA ≥ 1.5 standard deviation ( SD ) ageadjusted normal value ; ) . fat fraction ≤ 17 % . More 1 joint replacement ( revision surgery repair replacement previously replace joint allow ) . Pregnant , lactate permenopausal woman . Active , uncontrolled infection , hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Major concurrent disorder ( i.e . cancer , renal disease ) disorder known affect bone ( e.g . uncontrolled thyroid disease , hyperparathyroidism , hypoparathyroidism , gastrectomy , malabsorption , inflammatory bowel disease , rheumatoid arthritis , ankylose spondylitis ) . Medications know affect bone homeostasis ( e.g . chronic oral corticosteroid , anticonvulsant , phenytoin phenobarbital , hyperphysiological dos estrogen , define &gt; 0.625mg , androgen , bisphosphates , calcitonin ) within first 2 month first Cerezyme infusion . Emotional , behavioral psychological problem , judgment principal investigator , would interfere patient adequately comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Type I Gaucher disease</keyword>
	<keyword>Glucocerebrosidase Deficiency Disease</keyword>
</DOC>